Bronchial Vascular Remodeling Is Attenuated by Anti-IL-17 in Asthmatic Responses Exacerbated by LPS

Imagem de Miniatura
Arquivos
art_CAMARGO_Bronchial_Vascular_Remodeling_Is_Attenuated_by_AntiIL17_in_2020.PDF.pdf (17.22 MB)
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
ANDRADE, Felipp Costa Pinto de
PRADO, Carla Maximo
Citação
FRONTIERS IN PHARMACOLOGY, v.11, article ID 1269, 18p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction Although the major alterations associated with asthma are related to the airways, there is also evidence of the importance of peribronchial vascular inflammation and remodeling in its pathophysiology. Objectives To determine the effects of anti-IL-17 therapy on peribronchial vessels of an asthma model exacerbated by lipopolysaccharide. Methods We evaluated several factors, including lung function, inflammation, oxidative stress, vascular remodeling, and signaling pathways present in the peribronchial vessels of 66 male BALB/c mice exposed to ovalbumin and treated (or not) treated with anti-IL-17. Twenty-four hours before the end of the experimental protocol, groups of sensitized animals (OVA-LPS and OVA-LPS anti-IL-17) also received LPS. Results The OVA-LPS-anti-IL-17 group presented a decrease in several factors [airway resistance and elastance, bronchoalveolar lavage fluid (BALF) cell counts, inflammatory response, eosinophils, TSLP, IL-33, TARC, TNF-alpha, CD4+, CD8+, IL-4, IL-6, IL-10, IL-17, and VEGF positive cells/10(4)mu m(2), peribronchovascular edema, and angiogenesis], including remodeling (MMP-9, MMP-12, TIMP-1 and TGF-beta positive cells and volume fraction of collagen fibers I, collagen fibers III, collagen fibers V, decorin, lumican, actin, biglycan, fibronectin, and integrin), oxidative stress (iNOS positive cells and volume fraction of PGF2 alpha), and signaling pathways (FoxP3), as well as dendritic cells, NF-kB, ROCK-1, ROCK-2, STAT-1, and phosphor-STAT1-positive cells compared to OVA-LPS (p < 0.05). Conclusions In this model of LPS-induced asthma exacerbation, IL-17 inhibition represents a promising therapeutic strategy, indicating the potential of bronchial vascular control of Th2 and Th17 responses and the activation of the remodeling and oxidative stress pathways, associated with the control of signaling pathways.
Palavras-chave
anti-IL-17, vascular inflammation, LPS (lipopolysaccharide), asthma, vascular remodeling
URI
https://observatorio.fm.usp.br/handle/OPI/38243
Referências
  1. Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024
  2. Aldakheel FM, 2016, ALLERGY, V71, P741, DOI 10.1111/all.12865
  3. Angeli P, 2008, AM J PHYSIOL-LUNG C, V294, pL1197, DOI 10.1152/ajplung.00199.2007
  4. Araujo BB, 2008, EUR RESPIR J, V32, P61, DOI 10.1183/09031936.00147807
  5. Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797
  6. Barlow JL, 2011, CLIN EXP ALLERGY, V41, P1447, DOI 10.1111/j.1365-2222.2011.03806.x
  7. Bryan BA, 2010, FASEB J, V24, P3186, DOI 10.1096/fj.09-145102
  8. Camargo LD, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01835
  9. Chabot F, 2009, PRESSE MED, V38, P485, DOI 10.1016/j.lpm.2008.12.014
  10. Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557
  11. Chan BCL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00364
  12. Chetta A, 2005, CLIN EXP ALLERGY, V35, P1437, DOI 10.1111/j.1365-2222.2005.02360.x
  13. Choi YS, 2009, BLOOD, V114, P3117, DOI 10.1182/blood-2009-02-203372
  14. Connolly MJ, 2011, PULM PHARMACOL THER, V24, P1, DOI 10.1016/j.pupt.2010.09.001
  15. De Boever EH, 2014, J ALLERGY CLIN IMMUN, V133, P989, DOI 10.1016/j.jaci.2014.01.002
  16. dos Santos TM, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01183
  17. EVANS TW, 1987, J APPL PHYSIOL, V63, P479
  18. Feltis BN, 2007, THORAX, V62, P314, DOI 10.1136/thx.2006.069229
  19. GOLDIE AS, 1995, JAMA-J AM MED ASSOC, V274, P172, DOI 10.1001/jama.274.2.172
  20. Hayashi H, 2013, INFLAMMATION, V36, P830, DOI 10.1007/s10753-013-9609-z
  21. Hoang MV, 2004, P NATL ACAD SCI USA, V101, P1874, DOI 10.1073/pnas.0308525100
  22. Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928
  23. Huang Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep36551
  24. Bittencourt-Mernak MI, 2017, AM J PHYSIOL-LUNG C, V312, pL217, DOI 10.1152/ajplung.00444.2015
  25. Kang MJ, 2012, AM J RESP CRIT CARE, V185, P1205, DOI 10.1164/rccm.201108-1545OC
  26. Kotsimbos ATC, 1997, MEM I OSWALDO CRUZ, V92, P75, DOI 10.1590/S0074-02761997000800012
  27. Lazaar AL, 2003, AM J MED, V115, P652, DOI 10.1016/j.amjmed.2003.07.010
  28. Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3
  29. Lu S, 2015, J IMMUNOL, V194, P3557, DOI 10.4049/jimmunol.1400829
  30. Murugaiyan G, 2009, J IMMUNOL, V183, P2435, DOI 10.4049/jimmunol.0900568
  31. Nakashima AS, 2008, J APPL PHYSIOL, V104, P1778, DOI 10.1152/japplphysiol.00830.2007
  32. Otani K, 2004, J ASTHMA, V41, P271, DOI 10.1081/JAS-120026083
  33. Panariti A, 2018, CLIN EXP ALLERGY, V48, P365, DOI 10.1111/cea.13093
  34. Sakoda CPP, 2016, ACTA HISTOCHEM, V118, P615, DOI 10.1016/j.acthis.2016.07.001
  35. Peters A, 2014, CURR OPIN IMMUNOL, V28, P42, DOI 10.1016/j.coi.2014.01.017
  36. Pigati PA, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0073-4
  37. Pinheiro NM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120441
  38. Possa SS, 2012, AM J PHYSIOL-LUNG C, V303, pL939, DOI 10.1152/ajplung.00034.2012
  39. Postma Dirkje S, 2006, Proc Am Thorac Soc, V3, P434, DOI 10.1513/pats.200601-006AW
  40. Prado CM, 2011, EXP LUNG RES, V37, P259, DOI 10.3109/01902148.2010.538289
  41. Puttur F, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav7638
  42. Puxeddu I, 2005, J ALLERGY CLIN IMMUN, V116, P531, DOI 10.1016/j.jaci.2005.06.007
  43. RighettI RF, 2014, RESP PHYSIOL NEUROBI, V192, P134, DOI 10.1016/j.resp.2013.12.012
  44. Shan S, 2016, IMMUNOLOGY, V148, P83, DOI 10.1111/imm.12589
  45. Soon E, 2010, CIRCULATION, V122, P921, DOI 10.1161/CIRCULATIONAHA.109.933762
  46. Starkhammar M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032110
  47. Stojkovic S, 2014, J THROMB HAEMOST, V12, P948, DOI 10.1111/jth.12581
  48. Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156
  49. Sundrud MS, 2013, SEMIN IMMUNOL, V25, P263, DOI 10.1016/j.smim.2013.10.021
  50. Vieira RP, 2008, AM J PHYSIOL-LUNG C, V295, pL670, DOI 10.1152/ajplung.00465.2007
  51. Walters JA, 2008, THORAX, V63, P408, DOI 10.1136/thx.2007.082859
  52. Wang Yan, 2003, Zhonghua Jiehe He Huxi Zazhi, V26, P790
  53. Watanabe T, 2004, AM J RESP CRIT CARE, V169, P105, DOI 10.1164/rccm.200302-239OC
  54. Wilson JW, 2003, CURR ALLERGY ASTHM R, V3, P153, DOI 10.1007/s11882-003-0028-3
  55. Zanini A, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-132

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - ODS/03